Health Care & Life Sciences » Pharmaceuticals | Yuyu Pharma Inc.

Yuyu Pharma Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
61,985
61,994
62,816
69,743
83,593
83,096
Cost of Goods Sold (COGS) incl. D&A
27,132
30,030
32,094
39,279
44,224
43,032
Gross Income
34,852
31,964
30,722
30,465
39,369
40,065
SG&A Expense
30,993
29,965
29,195
28,878
34,483
34,531
EBIT
3,718
1,836
1,372
1,424
4,746
5,328
Unusual Expense
295
-
2,680
3,218
705
229
Non Operating Income/Expense
88
651
6,541
1,318
1,685
151
Interest Expense
246
256
304
297
507
1,121
Pretax Income
3,586
2,453
7,911
656
6,402
4,648
Income Tax
600
698
309
122
698
336
Equity in Affiliates
-
177
239
375
-
-
Consolidated Net Income
2,986
1,932
7,363
404
5,704
4,312
Net Income
2,979
1,877
7,467
253
6,040
4,020
Net Income After Extraordinaries
2,979
1,877
7,467
253
6,040
4,020
Net Income Available to Common
2,979
1,877
7,467
253
6,040
3,748
EPS (Basic)
507.01
319.22
1,185.86
40.36
917.00
639
Basic Shares Outstanding
6
6
6
6
7
6
EPS (Diluted)
507.01
318.30
1,185.86
40.36
906.09
563.07
Diluted Shares Outstanding
6
6
6
6
7
7
EBITDA
5,267
3,469
2,882
2,966
6,689
7,455
Other Operating Expense
141
163
155
163
140
206
Non-Operating Interest Income
159
222
241
117
175
251
Minority Interest Expense
7
55
104
151
336
292
Equity in Affiliates (Pretax)
162
-
-
-
1,008
269

About Yuyu Pharma

View Profile
Address
94 Bio valley 1-ro
Jecheon NC 27159
Korea, Republic Of
Employees -
Website http://www.yuyu.co.kr
Updated 07/08/2019
Yuyu Pharma, Inc. engages in the manufacture and sale of pharmaceuticals. It operates through the Prescription and Non-prescription divisions. The Prescription division provides circulatory improvement agents, bone metabolism ameliorants, antihypertensive drugs, topical corticosteroids, antiplatelet agents, gout prepartions, angina pectoris drugs, osteoporosis drugs, antidiabetic agents, antibiotics, antiulcerants, varicose preparations, antitubercular agents, and hemorrhoidal.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.